MA44237A - Méthodes et compositions pour l'administration au système nerveux cental d'arylsulfatase a - Google Patents

Méthodes et compositions pour l'administration au système nerveux cental d'arylsulfatase a

Info

Publication number
MA44237A
MA44237A MA044237A MA44237A MA44237A MA 44237 A MA44237 A MA 44237A MA 044237 A MA044237 A MA 044237A MA 44237 A MA44237 A MA 44237A MA 44237 A MA44237 A MA 44237A
Authority
MA
Morocco
Prior art keywords
arylsulfatase
administration
compositions
methods
nervous system
Prior art date
Application number
MA044237A
Other languages
English (en)
French (fr)
Inventor
Margaret Wasilewski
Anna Wijatyk
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA44237A publication Critical patent/MA44237A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA044237A 2016-02-17 2017-02-17 Méthodes et compositions pour l'administration au système nerveux cental d'arylsulfatase a MA44237A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662296563P 2016-02-17 2016-02-17
US201762453864P 2017-02-02 2017-02-02

Publications (1)

Publication Number Publication Date
MA44237A true MA44237A (fr) 2021-06-02

Family

ID=58192404

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044237A MA44237A (fr) 2016-02-17 2017-02-17 Méthodes et compositions pour l'administration au système nerveux cental d'arylsulfatase a

Country Status (10)

Country Link
US (3) US11020461B2 (https=)
EP (1) EP3416678A1 (https=)
JP (4) JP2019509270A (https=)
CN (2) CN108883162A (https=)
AU (1) AU2017220100B2 (https=)
BR (1) BR112018016874A2 (https=)
CA (1) CA3014909A1 (https=)
MA (1) MA44237A (https=)
MX (2) MX2018009937A (https=)
WO (1) WO2017143233A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019126376A1 (en) * 2017-12-19 2019-06-27 Shire Human Genetic Therapies, Inc. Purified arylsulfatase a and compositons thereof
BR112021021908A2 (pt) * 2019-05-03 2022-02-01 Univ Pennsylvania Composições úteis no tratamento da leucodistrofia metacromática

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
NZ605874A (en) * 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of heparan n-sulfatase
SMT201600385T1 (it) * 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
NZ605873A (en) * 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of arylsulfatase a
CN103179980B (zh) * 2010-06-25 2016-09-28 夏尔人类遗传性治疗公司 艾杜糖醛酸-2-硫酸酯酶的cns递送的方法和组合物

Also Published As

Publication number Publication date
EP3416678A1 (en) 2018-12-26
WO2017143233A1 (en) 2017-08-24
US20210315981A1 (en) 2021-10-14
AU2017220100B2 (en) 2024-04-04
CN108883162A (zh) 2018-11-23
JP2023159405A (ja) 2023-10-31
MX2024004034A (es) 2024-04-24
MX2018009937A (es) 2018-11-29
AU2017220100A1 (en) 2018-08-30
CN117224659A (zh) 2023-12-15
US20250099555A1 (en) 2025-03-27
US11020461B2 (en) 2021-06-01
JP2024102370A (ja) 2024-07-30
CA3014909A1 (en) 2017-08-24
BR112018016874A2 (pt) 2019-02-05
JP2021169528A (ja) 2021-10-28
JP2019509270A (ja) 2019-04-04
US20200179492A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
EP3679141A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING LDHA EXPRESSION
EP3510152A4 (en) METHOD AND COMPOSITIONS FOR MODULATING GENE EXPRESSION
MA47206A (fr) Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3
EP3362104A4 (en) METHOD AND COMPOSITIONS USING CPF1 FOR RNA-GUIDED GEN EDITING
EP3355954A4 (en) RELEASE PROCEDURE AND COMPOSITIONS
MA50546A (fr) Compositions et méthodes pour l'internalisation d'enzymes
EP3402549A4 (en) MICRONADELE COMPOSITIONS AND METHOD FOR USE THEREOF
MA42950A (fr) Administration d'agents de potentialisation de cftr modifiés au deutérium
EP3353309A4 (en) COMPOSITIONS AND METHOD FOR GENERIC EDITING
EP3411414A4 (en) COMPOSITIONS AND METHOD FOR TARGETED CYTOKINE RELIEF
EP4034253A4 (en) Compositions and methods for increasing the efficacy of immunotherapies and vaccines
EP3532613A4 (en) METHOD AND COMPOSITIONS FOR RNA MAPPING
MA71409A (fr) Constructions d'anticorps pour dll3 et cd3
MA43515A (fr) Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
EP2850188A4 (en) COMPOSITIONS AND METHOD FOR MODULATING THE EXPRESSION OF THE HEMOGLOBIN GENE FAMILIES
MA71468A (fr) Compositions et méthodes pour diminuer l'expression de tau
EP2850190A4 (en) COMPOSITIONS AND METHOD FOR MODULATING MECP2 EXPRESSION
EP2850182A4 (en) COMPOSITIONS AND METHODS FOR MODULATING ATP2A2 GENE EXPRESSION
EP3383917A4 (en) Novel anti-claudin antibodies and methods of use
EP3302588A4 (en) COMPOSITIONS AND METHODS FOR LAYERING ON SURFACES
MA46842A (fr) Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8
MA43378A (fr) Compositions et méthodes pour la reduction de la réponse immunitaire contre récepteurs d'antigène chimériques
EP3402883A4 (en) COMPOSITIONS AND METHODS FOR THE SEQUENCING OF NUCLEIC ACIDS
EP3573618A4 (en) COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION
EP3452108A4 (en) METHOD AND DEVICES FOR THE PRODUCTION OF ULTRASONIC CONTRASTING AGENTS